298 related articles for article (PubMed ID: 26219303)
1. Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner.
Mochizuki-Kashio M; Aoyama K; Sashida G; Oshima M; Tomioka T; Muto T; Wang C; Iwama A
Blood; 2015 Sep; 126(10):1172-83. PubMed ID: 26219303
[TBL] [Abstract][Full Text] [Related]
2. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.
Muto T; Sashida G; Oshima M; Wendt GR; Mochizuki-Kashio M; Nagata Y; Sanada M; Miyagi S; Saraya A; Kamio A; Nagae G; Nakaseko C; Yokote K; Shimoda K; Koseki H; Suzuki Y; Sugano S; Aburatani H; Ogawa S; Iwama A
J Exp Med; 2013 Nov; 210(12):2627-39. PubMed ID: 24218139
[TBL] [Abstract][Full Text] [Related]
3. PRC2 insufficiency causes p53-dependent dyserythropoiesis in myelodysplastic syndrome.
Aoyama K; Shinoda D; Suzuki E; Nakajima-Takagi Y; Oshima M; Koide S; Rizq O; Si S; Tara S; Sashida G; Iwama A
Leukemia; 2021 Apr; 35(4):1156-1165. PubMed ID: 32820269
[TBL] [Abstract][Full Text] [Related]
4. Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells.
Mochizuki-Kashio M; Mishima Y; Miyagi S; Negishi M; Saraya A; Konuma T; Shinga J; Koseki H; Iwama A
Blood; 2011 Dec; 118(25):6553-61. PubMed ID: 22042701
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia.
Xu B; On DM; Ma A; Parton T; Konze KD; Pattenden SG; Allison DF; Cai L; Rockowitz S; Liu S; Liu Y; Li F; Vedadi M; Frye SV; Garcia BA; Zheng D; Jin J; Wang GG
Blood; 2015 Jan; 125(2):346-57. PubMed ID: 25395428
[TBL] [Abstract][Full Text] [Related]
6. Ezh1 Targets Bivalent Genes to Maintain Self-Renewing Stem Cells in Ezh2-Insufficient Myelodysplastic Syndrome.
Aoyama K; Oshima M; Koide S; Suzuki E; Mochizuki-Kashio M; Kato Y; Tara S; Shinoda D; Hiura N; Nakajima-Takagi Y; Sashida G; Iwama A
iScience; 2018 Nov; 9():161-174. PubMed ID: 30396150
[TBL] [Abstract][Full Text] [Related]
7. Polycomb Repressive Complex 2 Proteins EZH1 and EZH2 Regulate Timing of Postnatal Hepatocyte Maturation and Fibrosis by Repressing Genes With Euchromatic Promoters in Mice.
Grindheim JM; Nicetto D; Donahue G; Zaret KS
Gastroenterology; 2019 May; 156(6):1834-1848. PubMed ID: 30689973
[TBL] [Abstract][Full Text] [Related]
8. Ezh2 regulates the Lin28/let-7 pathway to restrict activation of fetal gene signature in adult hematopoietic stem cells.
Oshima M; Hasegawa N; Mochizuki-Kashio M; Muto T; Miyagi S; Koide S; Yabata S; Wendt GR; Saraya A; Wang C; Shimoda K; Suzuki Y; Iwama A
Exp Hematol; 2016 Apr; 44(4):282-96.e3. PubMed ID: 26773568
[TBL] [Abstract][Full Text] [Related]
9. EZH1 in germ cells safeguards the function of PRC2 during spermatogenesis.
Mu W; Starmer J; Shibata Y; Yee D; Magnuson T
Dev Biol; 2017 Apr; 424(2):198-207. PubMed ID: 28254491
[TBL] [Abstract][Full Text] [Related]
10. Sequential regulation of hemogenic fate and hematopoietic stem and progenitor cell formation from arterial endothelium by Ezh1/2.
Soto RA; Najia MAT; Hachimi M; Frame JM; Yette GA; Lummertz da Rocha E; Stankunas K; Daley GQ; North TE
Stem Cell Reports; 2021 Jul; 16(7):1718-1734. PubMed ID: 34143974
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic roles of enhancer of zeste homolog 1/2 in hematological malignancies.
Nakagawa M; Kitabayashi I
Cancer Sci; 2018 Aug; 109(8):2342-2348. PubMed ID: 29845708
[TBL] [Abstract][Full Text] [Related]
12. Polycomb repressive complex 2 component Suz12 is required for hematopoietic stem cell function and lymphopoiesis.
Lee SC; Miller S; Hyland C; Kauppi M; Lebois M; Di Rago L; Metcalf D; Kinkel SA; Josefsson EC; Blewitt ME; Majewski IJ; Alexander WS
Blood; 2015 Jul; 126(2):167-75. PubMed ID: 26036803
[TBL] [Abstract][Full Text] [Related]
13. EZH2 in normal hematopoiesis and hematological malignancies.
Herviou L; Cavalli G; Cartron G; Klein B; Moreaux J
Oncotarget; 2016 Jan; 7(3):2284-96. PubMed ID: 26497210
[TBL] [Abstract][Full Text] [Related]
14. Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons.
Henriquez B; Bustos FJ; Aguilar R; Becerra A; Simon F; Montecino M; van Zundert B
Mol Cell Neurosci; 2013 Nov; 57():130-43. PubMed ID: 23932971
[TBL] [Abstract][Full Text] [Related]
15. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
[TBL] [Abstract][Full Text] [Related]
16. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
17. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
[TBL] [Abstract][Full Text] [Related]
18. Nucleosome-binding activities within JARID2 and EZH1 regulate the function of PRC2 on chromatin.
Son J; Shen SS; Margueron R; Reinberg D
Genes Dev; 2013 Dec; 27(24):2663-77. PubMed ID: 24352422
[TBL] [Abstract][Full Text] [Related]
19. [Epigenetic aberrations in adult T-cell leukemia/lymphoma and development of a novel EZH1/2 inhibitor].
Yamagishi M
Rinsho Ketsueki; 2018; 59(4):432-438. PubMed ID: 29743404
[TBL] [Abstract][Full Text] [Related]
20. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.
Khan SN; Jankowska AM; Mahfouz R; Dunbar AJ; Sugimoto Y; Hosono N; Hu Z; Cheriyath V; Vatolin S; Przychodzen B; Reu FJ; Saunthararajah Y; O'Keefe C; Sekeres MA; List AF; Moliterno AR; McDevitt MA; Maciejewski JP; Makishima H
Leukemia; 2013 Jun; 27(6):1301-9. PubMed ID: 23486531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
